Cerus Co. (NASDAQ:CERS – Get Rating)'s share price gapped up prior to trading on Friday . The stock had previously closed at $4.05, but opened at $4.23. Cerus shares last traded at $4.14, with a volume of 13,468 shares trading hands.
Cerus Trading Up 2.5 %
The firm has a market capitalization of $734.92 million, a price-to-earnings ratio of -17.29 and a beta of 1.14. The firm's 50 day moving average is $5.08 and its 200 day moving average is $5.13. The company has a quick ratio of 1.73, a current ratio of 2.08 and a debt-to-equity ratio of 0.53.
Get
Cerus alerts:
Insiders Place Their Bets
In other Cerus news, insider Richard J. Benjamin sold 10,000 shares of the firm's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $5.12, for a total value of $51,200.00. Following the sale, the insider now directly owns 172,665 shares in the company, valued at approximately $884,044.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.33% of the company's stock.
Institutional Investors Weigh In On Cerus
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MQS Management LLC acquired a new position in Cerus during the fourth quarter valued at approximately $69,000. Lazard Asset Management LLC grew its stake in shares of Cerus by 59.2% in the first quarter. Lazard Asset Management LLC now owns 13,453 shares of the biotechnology company's stock valued at $73,000 after acquiring an additional 5,004 shares in the last quarter. Baker Tilly Wealth Management LLC acquired a new position in shares of Cerus in the second quarter valued at about $74,000. WMS Partners LLC acquired a new position in shares of Cerus in the fourth quarter valued at about $75,000. Finally, Nan Fung Group Holdings Ltd bought a new stake in Cerus during the first quarter worth about $78,000. Institutional investors and hedge funds own 84.72% of the company's stock.
Cerus Company Profile
(Get Rating)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
See Also
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.
